FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation
FDA approves new drug for the treatment of adults with acute myeloid leukemia who have a specific genetic mutation and a companion diagnostic to detect specific mutations in the IDH1 gene in patients with AML
Source: Food and Drug Administration - Category: American Health Source Type: news
More News: Acute Leukemia | Acute Myeloid Leukemia | American Health | Food and Drug Administration (FDA) | Genetics | Leukemia